IntroDuctIon
hPSCs are an important tool for regenerative medicine and disease modeling in vitro 1,2 . To date, however, protocols for the differentiation of hPSCs into specific kidney cell types with high efficiency, without the need for less well-defined inducers such as embryonic spinal cords, have eluded many researchers [3] [4] [5] . Substantial advances have been made within the past decade that draw upon our knowledge of kidney development to differentiate PSCs into cells of the kidney lineage [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . By recapitulating metanephric kidney development in vitro, we generated NPCs with 80-90% purity within 9 d, without subpopulation selection during the directed differentiation protocol 15 . hPSC-derived NPCs possess the developmental potential of their in vivo counterparts 15 , forming renal vesicles that self-pattern into nephron structures. In both 2D and 3D culture, NPCs form kidney organoids containing epithelial nephron-like structures expressing markers of podocytes, proximal tubules, loops of Henle and distal tubules in organized, continuous structures that resemble the nephron in vivo 15 .
Development of the protocol
A recent study by Taguchi et al. revealed that the origin of the metanephros is distinct from the ureteric bud or pro/mesonephric lineages 5 . They showed that the metanephros arises from the posterior intermediate mesoderm, whereas the ureteric bud and the pro/mesonephros are derived from the anterior intermediate mesoderm. Therefore, we hypothesized that the specific induction of posterior intermediate mesoderm cells from hPSCs would greatly facilitate the induction of NPCs and avoid contamination with pronephric or mesonephric cells. Previous studies revealed that locations in the primitive streak define the subsequent differentiation into each segment of mesoderm-i.e., paraxial, intermediate or lateral-plate mesoderm 16 . In addition, the timing of cell migration from the primitive streak defines the anterior-posterior axis in the mesoderm, suggesting that the late stage of the primitive streak induces posterior mesoderm 17 . We optimized the time of treatment with the GSK-3β inhibitor CHIR99201 (CHIR), an inducer of the primitive streak, to induce late-stage primitive streak. In addition, we used BMP4 inhibitors, as high BMP4 activity induces more posterior aspects of the primitive streak, which develop into lateral-plate mesoderm 18 . With this approach, we developed a highly efficient protocol to induce SIX2 + SALL1 + WT1 + PAX2 + EYA1 + NPCs from both human ESCs and iPSCs with 80-90% efficiency within 9 d of differentiation. After the induction of NPCs, we transiently treated cells with CHIR (3 µM), generating multisegmented nephron structures with characteristics of podocytes, proximal tubules, loops of Henle and distal tubules sequenced in a tubule that self-assembled in a manner that reflects normal nephron structure 15 . Further analyses of other organoid compartments revealed CDH1 + AQP2 + tubules and PDGFRβ + , endomucin + or α-SMA + interstitial cells in the kidney organoids ( Supplementary Fig. 1 , R.M. and N. Gupta, data not shown). Collectively, our protocols generated kidney organoids consisting of multiple kidney compartments with cellular proportions similar to those of in vivo kidneys, in which nephrons occupy nearly 90% of the renal cortex 19 .
By generating iPSCs from patients with inherited kidney diseases, and producing kidney organoids from these cells, the pathogenesis of inherited kidney diseases could be explored. Moreover, it is also possible to study inherited kidney diseases by introducing targeted mutations with CRISPR/Cas9 genome editing in hPSCs and taking advantage of comparisons of organoids from mutated and parental lines with an otherwise uniform genetic background 14, 21, 22 . These approaches will enable the analysis of inheritable disease pathophysiology and allow for drug screening in vitro to find new therapeutic approaches. Another application of kidney organoids will be to test the nephrotoxicity of drugs in predictive toxicology based on the genotypic characteristics of an individual. As the kidney organoids contain multiple cell types, reflecting sequential segments of the nephron from podocytes to distal tubules, it will be possible to assign drug toxicity to specific nephron segments. The maintenance of a differentiated phenotype in vitro will also allow for cellular biochemical analyses and the study of inter-compartmental interactions that may mimic the in vivo status more closely than typical cell culture studies, in which the cells are generally dedifferentiated. The presence of CDH1 + AQP2 + tubules and PDGFRβ + , endomucin + or α-SMA + interstitial cells will permit studies of nephron-interstitial cell interactions. Ultimately, the protocol has the potential to serve as a foundation to provide organoids for kidney regenerative therapies.
Researchers can choose 2D or 3D kidney organoid generation, based on their study goals. Generation of kidney organoids with 2D culture is possible even with low-efficiency induction of NPCs; therefore, it would be easier to generate kidney organoids with minimal adjustment of differentiation protocols. Generation of kidney organoids with 3D culture requires highly efficient induction of NPCs; however, it enables the generation of frozen sections, which allows immunohistochemistry investigation with multiple antibodies from the same sample. For detailed evaluation of disease phenotypes, 3D culture is recommended, as structures of nephrons are more similar to in vivo nephrons, with clear lumen formation of tubules, than with 2D culture.
Comparison with other methods
On comparing our protocol with previously published protocols to induce kidney lineage cells, there are many differences in efficiency, specificity and simplicity. Our protocols yield NPCs, with much higher induction efficiency, from both human embryonic stem cells (hESCs) and human induced pluripotent stem cell (hiPSCs), as compared with previous studies, including our own 3, 4, 13, 14, 23 . High induction efficiency at each step of differentiation, simultaneously, indicates high specificity of kidney induction. Taguchi et al. 5 reported relatively high efficiency (~60%) of SIX2 + cell induction with embryoid body formation, yet coculture with mouse embryonic spinal cords is required to generate kidney epithelial cells, whereas our protocols use monolayer culture and chemically defined components that do not require preparation of pregnant mice and mouse embryonic spinal cords for kidney organoid generation 5 . We were able to generate NPCs and organoids using fully defined conditions without the addition of any nonpurified factors, which is desirable for regenerative utility in humans. In addition, our protocols use 96-well, round-bottom, ultra-lowattachment plates to generate 3D kidney organoids, which enables mass production of kidney organoids, whereas the other protocols for generating organoids require pelleting cells in Eppendorf tubes or coculture with mouse embryonic spinal cords 5, 13 . As previous studies have shown, the efficiency of the same differentiation protocol differs in different hPSC lines 24 ; therefore, adjustments must be made to achieve similar results in various lines. We explain how to adjust the protocol for different lines of hPSCs, which further facilitates the applicability of our differentiation protocols. The dose of growth factors can greatly influence the costs of the directed differentiation protocols. We were able to use lower doses of FGF9 than those used in the excellent protocol of Takasato et al. 13 . This has substantial financial advantages at the present time.
Other protocols result in the generation of CD31 + endothelialike cells 13, 14 and CDH1 + GATA3 + collecting-duct-like cells 13 . We now have unpublished data that document the presence of CDH1 + AQP2 + tubules and PDGFRβ + , endomucin + or α-SMA + interstitial cells in the kidney organoids (Supplementary Fig. 1 ; R.M. and N. Gupta, data not shown). The cells expressing these markers require more characterization, and one of our goals is to understand how these populations might be enhanced in our protocol. Non-nephron cells are useful for establishing a multicompartment environment in the kidney organoids, potentially leading to vascularization of glomerular and tubulointerstitial structures. The ability to generate NPCs with high efficiency and ultimately multisegmented nephrons serves as a very good starting point for subsequent bioengineering of functional kidney tissues.
Limitations
The differentiation efficiency of our protocol is affected by the variability intrinsic to hPSC lines. We explain how to adjust the protocol for different cell lines grown initially in different culture conditions, reflecting our experience with two different culture media and multiple hPSC lines. We recommend the use of the H9 cell line and ReproFF2 medium as the simplest methods of achieving high differentiation efficiency. We believe that our adjustment methods will enable researchers in different environments to generate NPCs and kidney organoids with different culture systems and different cell lines. Another limitation of our protocols is that the cells in the interstitial space of kidney organoids were not well characterized in our original study because of a lack of definitive morphological characteristics and validated antibodies in the human kidney samples. Those cells were presumably derived from a SIX2-negative population, which accounted for 10-20% of the cells at the NPC stage, and could be collecting duct cells, pericytes, endothelial cells, smooth muscle cells, fibroblasts or others 12, [25] [26] [27] [28] [29] . Our recent unpublished results showed CDH1 + AQP2 + tubules (characteristic of connecting tubules and collecting ducts 25 ) and PDGFRβ + (characteristic of pericytes 26 ), endomucin + (characteristic of endothelial cells 27 ) or α-SMA + (characteristic of myofibroblasts 26 ) interstitial cells in the organoids ( Supplementary   Fig. 1 , R.M. and N. Gupta, data not shown); however, further definitive analyses of these cells are ongoing. We therefore hope that further studies by us and other investigators will elucidate the characteristics and state of cell types in the interstitial space. We believe that the organoid system derived from our protocols is appropriate for the study of the interactions between nephron epithelial cells and interstitial cells in a human in vitro model system that recapitulates the complexities of these interactions in the intact organ. In this way, we hope to unlock new insight into processes such as kidney fibrosis, a fundamental process resulting in chronic kidney disease.
Experimental design Feeder-free hPSC culture in ReproFF2 medium (Steps 1-6).
Our protocols use feeder-free hPSC culture in ReproFF2 medium with lactose-dehydrogenase-elevating virus (LDEV)-free hESCqualified Geltrex-coated plates 4, 15 . We maintain hPSCs in six-well plates coated with 1% LDEV-free hESC-qualified Geltrex with ReproFF2 medium, supplemented with fibroblast growth factor 2 (FGF2), at a concentration of 10 ng/ml (Steps 1-6). If hPSCs were initially cultured on mouse embryonic fibroblast (MEF) feeders, we recommend passaging the cells at least 5 times under feederfree conditions with ReproFF2. If hPSCs cannot be maintained in ReproFF2, we recommend using StemFit Basic medium supplemented with FGF2 (10 ng/ml) using six-well plates coated with 1% LDEV-Free hESC-qualified Geltrex 28 (Box 1, R.M., data not shown). hPSCs are passaged every 7 d. The difference between using ReproFF2 and using StemFit Basic medium is the method used to passage the cells. With ReproFF2, cells are passaged by clump passage, an original passaging method for hPSCs that is used with many types of hPSC maintenance media. On the other hand, with StemFit Basic medium, single-cell passaging with a ROCK inhibitor is used. (Steps 7-13). We usually prepare two wells of six-well plates, and use one well for differentiation and one well for continued passaging. Plating density substantially affects the differentiation efficiency, and each hPSC line requires adjustment. For H9 cells, ~20,000 cells/cm 2 was the best plating density in our experience. For HDF-α iPSCs, ~14,000 cells/cm 2 was optimal. Pluripotency of hPSCs needs to be well maintained in the undifferentiated cells, and hence differentiated colonies need to be removed by aspiration. To prepare cells for differentiation, the cells are dissociated with Accutase for 15 min, resuspended in ReproFF2 supplemented with 10 ng/ml FGF2 and 10 µM Y27632 (ref. 29) , and plated in 24-well plates precoated with 1% LDEV-Free hESC-qualified Geltrex. The cells are cultured for 72 h until they reach ~50% confluency. Figure 2 shows the cellular morphology upon initiation of differentiation. The confluency at initiation substantially affects the differentiation efficiency; therefore, we strongly recommend the preparation of different plating densities until you find the best conditions. First, the cells are briefly washed with PBS once to remove the remnant of ReproFF2 (or StemFit). Then, differentiation is initiated with CHIR (ref. 30 ) at a concentration of 3-10 µM, with or without a BMP4 inhibitor (Noggin at 5-25 ng/ml or dorsomorphin at 100-500 nM). Each hPSC line requires a CHIR dose adjustment. The highest dose that does not lead to cell detachment or death during 4 d of CHIR treatment is recommended. The addition of a BMP4 inhibitor depends on the cell line and the maintenance conditions that you use. When we use H9 cells maintained in ReproFF2, we do not require the addition of a BMP4 inhibitor to 8 µM CHIR. For HDF, 10 µM CHIR with 5 ng/ml of Noggin was best. Addition of a BMP4 inhibitor does not change the subsequent differentiation protocol. If you use other cell lines or other culture media, adjust the protocol as follows. First, adjust the plating cell number to obtain 50% confluency when differentiation is initiated. Second, find the highest concentration of CHIR (3-10 µM) that does not lead to cell detachment and death during 4 d of CHIR treatment. Third, test the addition of a BMP4 inhibitor (Noggin at a concentration of 5-25 ng/ml or dorsomorphin at a concentration of 100-500 nM), if the adjustment of the plating cell number and CHIR is not sufficient to induce SIX2 + cells. This first step of differentiation generally takes 4 d. The medium should be changed on day 2 of differentiation. On day 4 of differentiation, the cells form 'loosely dense' clusters ( Fig. 2) . This identifies the best time to proceed to the next step of differentiation, which involves treating the cells with activin A at a concentration of 10 ng/ml. After 3 d of activin A treatment, the markers for posterior intermediate mesoderm, namely WT1 and HOXD11, become positive. Next, the cells are treated with FGF9, 10 ng/ml, for 2 d to induce NPCs. On day 9 of differentiation, a critical marker for NPCs, SIX2, becomes positive. SIX2 staining is very bright when differentiation is induced appropriately (Fig. 3a) .
Preparation of hPSCs for differentiation (Steps 7-13).

Nephron progenitor cell induction (Steps 14-22).
Kidney organoid induction (Step 23).
From this nephron progenitor cell stage, we can apply the same differentiation treatment in either 2D (Step 23A) or 3D (Step 23B) culture. When we switch to 3D culture, we use 96-well, round-bottom, ultra-low-attachment plates, and plate 100,000 cells/well. Usually, we obtain 2-3 million cells from one well of a 24-well plate, which is sufficient to generate many organoids. In both 2D and 3D culture, we treat NPCs with 3 µM CHIR and FGF9, 10 ng/ml, for 2 d to induce pretubular aggregates (PAX8 + LHX1 + ). Then, we switch back to FGF9 (10 ng/ml) alone, and culture the cells for 3 d to differentiate them into renal vesicles (PAX8 + LHX1 + LAM + ). After that, we use only the basic differentiation medium without any growth factors, and the cells form segmented-nephron structures within 1 week. The kidney organoids generated by our protocols are stable in the basic differentiation medium for up to 3 months, with feeding every 2-3 d. End-point analysis (Step 24). Typically, nephron structures are visible after 3-5 d of culture after the "renal vesicle stage" in 2D culture (Fig. 2) . In 2D culture, segmented-nephron structures can be analyzed by standard immunocytochemistry for markers of podocytes (PODXL), proximal tubules (Lotus tetraglonolobus lectin (LTL)), loops of Henle (cadherin 1 (CDH1), uromodulin) and distal tubules (CDH1) (Step 24A) (Fig. 3b) . In 3D culture, frozen sections can be made by standard protocols 31 , and nephron structures can be analyzed by immunohistochemistry (Step 24B) (Fig. 3c) . Alternatively, whole-mount staining can also be performed, which enables the observation of 3D nephron structures with confocal microscopy (Step 24C) (Fig. 3d) . Glomerular and tubular structures can occasionally be recognized with bright-field imaging near the surface of the organoids (Fig. 3e) .
Nephrotoxicity assay with cisplatin. There are a variety of possible applications for using NPCs and kidney organoids. As an example of one of these applications, we show a nephrotoxicity assay with cisplatin, a known nephrotoxicant ( Fig. 4; Box 2) . Once nephron structures have formed in kidney organoids (~day 21~), you can treat the organoids with agents to interrogate nephrotoxicity. We used KIM-1 staining to detect proximal tubular injury 32 . 2. Prepare the basic differentiation medium supplemented with 5 µM cisplatin (1:1,000 dilution) or sterile water as a negative control. The required volume for one well of a 3D culture or a 2D culture is 200 µl or 500 µl, respectively.  crItIcal step Make sure that there is no precipitation of cisplatin in the aliquot. If you see precipitation when the aliquot is taken from the freezer, warm up the aliquot in a water bath at 37 °C until the cisplatin is completely dissolved. 3. Gently aspirate the medium and add 200 µl (3D) or 500 µl (2D) of the basic differentiation medium supplemented with 5 µM cisplatin or sterile water.  crItIcal step Aspiration of kidney organoids will damage the tubules, which might result in induction of KIM-1 expression. Be careful not to aspirate the kidney organoids. 4. Culture the organoids at 37 °C in a 5% CO 2 incubator for 1 d. Harvest samples for your analyses (
Step 24A-C of the main PROCEDURE). (Steps 1-6 ). ReproFF2 Make 45-ml aliquots and store them at −20 °C for up to 6 months. Thaw an aliquot in a refrigerator overnight, and add FGF2 at a concentration of 10 ng/ml. Keep the medium in a refrigerator at 4 °C and use it within a week. StemFit Basic medium Make 45-ml aliquots after mixing solutions A and B, and store them at −20 °C for up to 6 months. Thaw an aliquot in a refrigerator overnight, and add FGF2 at a concentration of 10 ng/ml. Keep the medium in a refrigerator at 4 °C and use it within a week. Basic differentiation medium Add 5 ml of l-GlutaMAX to 500 ml of advanced RPMI 1640. Keep the medium in a refrigerator at 4 °C and use it within a month. Geltrex-coated plates Add LDEV-free hESC-qualified Geltrex to cold DMEM/F12 at a 1:100 ratio. Add 1 ml of the total volume to one well of a six-well plate or 300 µl to one well of a 24-well plate. Incubate the plates in a 37 °C incubator for at least 1 h. Store the coated plates in a refrigerator at 4 °C and use them within a week. Before seeding cells onto the plates, place the plates on a clean bench for at least 30 min at room temperature (20-25 °C) . ! cautIon Keep Geltrex on ice to prevent it from solidifying. PBS with Triton X-100, 0.3% (vol/vol) (500 ml) Add 1.5 ml of Triton X-100 to 500 ml of PBS and shake the solution well. Keep it at room temperature and use it within 12 months.  crItIcal All maintenance culture experiments described here use ReproFF2 and six-well plates coated with 1% LDEV-free hESC-qualified Geltrex. 1| Before passaging hPSCs, check the cell conditions and extent of spontaneous differentiation. Healthy undifferentiated hPSCs display a round colony morphology with a clear boundary. Proceed to the next step when the colonies are ~80% confluent. Unlike when grown on feeder culture, it is usual to observe some merged colonies.  crItIcal step Differentiated cells are usually located at the center of the colony when the size of each colony becomes too large. Some differentiated cells exhibit fibroblast-like morphology at the periphery of the colonies. In this case, it is difficult to remove the differentiated cells; therefore, it is better to start over with the transition to "feeder-free" conditions. ? trouBlesHootInG 2| Aspirate differentiated colonies by visual recognition. Small differentiated colonies will spontaneously disappear upon passaging; therefore, it is sufficient to remove only large differentiated colonies. Aspirate the ReproFF2 and add 200 µl of dissociation solution for human ES/iPSCs (CTK solution) to the center of the well to distribute the solution to the entire surface area. Place the cells in an incubator at 37 °C for 2 min until the edges of the colonies start to roll up. Aspirate the CTK solution and add 2 ml of PBS to wash away the remnants of the CTK solution.  crItIcal step It is important to be careful with treatment with CTK solution, which can be detrimental if cells are exposed to it for too long. If you wait too long, colonies will be lost when they are subsequently washed away with PBS. Hence, it is important to perform a visual check, with or without a microscope, for cell detachment after 2 min of exposure to CTK. When you notice the periphery of the colonies starting to roll up, it is time to proceed to the next step. We recommend checking cells every 15 s after 2 min of incubation with CTK solution.
3|
Aspirate the PBS and add 1 ml of ReproFF2. Detach the colonies using a cell scraper. Break up the colonies with a 1-ml pipette until you cannot see large aggregates. Pipetting is usually performed three to ten times (depending on confluency and cell lines).  crItIcal step The optimal size of colonies depends on the cell lines, the confluency and the passage number in feeder-free culture. The optimal diameter of colonies is 100-200 µm when the cells are optimized to feeder-free culture.
4|
Prepare a new plate and allow it to come to room temperature for 30 min. Aspirate the Geltrex solution from the new well, and add 1-1.7 ml of ReproFF2, depending on the passage ratio (total will be 2 ml).
5|
Transfer 330 µl-1 ml (1:1-1:3 ratio) of the colony fragments into one well of the new plate, and shake the plates gently to distribute the colonies equally in the well. 8| Aspirate the ReproFF2 and add 2 ml of PBS. Gently swirl the plate to wash out the remnants of the ReproFF2. Aspirate the PBS and add 500 µl of Accutase. Place the cells in an incubator at 37 °C and 5% CO 2 for 10 min.
Tap the plate to facilitate detachment of the cells. Incubate for another 5 min.
9|
After incubation for 15 min in total, detach and gently dissociate the cells with a 1-ml pipette until you cannot recognize cell aggregates. Prepare 15-ml tubes by adding 500 µl of ReproFF2.
10|
Collect the dissociated cells into 15-ml tubes filled with 500 µl of ReproFF2. Take 20 µl from the 15-ml tubes to a Cellometer Counting Chamber for cell counting. 
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Check the cell confluency. ~50% is the best for starting the differentiation. Aspirate the ReproFF2 and add 500 µl of PBS to wash out the remnants of the ReproFF2.  crItIcal step The confluency level when beginning the differentiation affects cell viability and differentiation efficiency. If the confluency is <50%, you can adjust the timing to start the differentiation later.
15|
Aspirate the PBS and add 500 µl of the differentiation basal medium supplemented with 3-10 µM CHIR with or without a BMP4 inhibitor (Noggin, 5-25 ng/ml, or dorsomorphin, 100-500 nM).  crItIcal step The concentration of CHIR and the addition of a BMP4 inhibitor depend on the cell line, the passage number and the maintenance culture conditions. For the H9 cell line, 8 µM CHIR was best with ReproFF2 culture. For HDF cells, 10 µM CHIR with 5 ng/ml Noggin was best. If you use other cell lines or other culture media, adjust the protocol as follows. First, adjust the plating cell number to obtain 50% confluency when differentiation is initiated. Second, find the highest concentration of CHIR (3-10 µM) that does not lead to cell detachment and death during 4 d of CHIR treatment. Third, test the addition of a BMP4 inhibitor (Noggin, 5-25 ng/ml, or dorsomorphin, 100-500 nM), if the adjustment of the plating cell number and CHIR concentration was not sufficient to induce SIX2 + cells. ? trouBlesHootInG
16|
Culture the cells at 37 °C in a 5% CO 2 incubator for 2 d.
17|
Aspirate the medium and feed the cells with 500 µl of fresh differentiation medium supplemented with the same concentration of CHIR (with or without a BMP4 inhibitor).
18|
19|
Check the morphology of the cells. The presence of loosely formed dense clusters of cells indicates the best time to switch to the next differentiation treatment (Fig. 2) . Usually, 96 h of differentiation is the best timing; however, you can adjust the timing depending on the morphology of the cells. Aspirate the medium and add 750 µl of the differentiation medium with activin A (10 ng/ml).  crItIcal step This stage is most important to achieving high efficiency of differentiation to NPCs. Check the morphology very carefully. If the cells still form a homogeneous flat monolayer (too loose, Fig. 2 ), feed them with the differentiation medium with the same concentration of CHIR (with or without a BMP4 inhibitor) and wait for one-half to one full day. If the cells form dome-like round clusters (too dense, Fig. 2 ), similar to undifferentiated mouse embryonic stem cells, it is often too late to proceed to the next step. Try again from the beginning of differentiation with a lower concentration of CHIR.
20|
Culture the cells at 37 °C in a 5% CO 2 ? trouBlesHootInG (ii) Aspirate the PBS and add 300 µl of Accutase per well of the 24-well plate. Incubate the cells at 37 °C in a 5% CO 2 incubator for 10-15 min. Prepare 15-ml tubes containing 300 µl of the basic differentiation medium supplemented with 3 µM CHIR and FGF9 (10 ng/ml). (iii) Dissociate the cells with a 1-ml pipette, and transfer the cells to the 15-ml tubes. Take 20 µl from the 15-ml tubes for cell counting with a Cellometer. (iv) Centrifuge the tubes at 300g at room temperature for 4 min. Count the cell number using a Cellometer. (v) Aspirate the medium and resuspend the cells in the basic differentiation medium supplemented with CHIR (3 µM) and FGF9 (10 ng/ml) at a density of 500,000 cells/ml. Plate 100,000 cells/well in 200 µl of the differentiation medium onto 96-well, round-bottom, ultra-low-attachment plates. (vi) Centrifuge the plates at 300g for 15 s, and culture the cells at 37 °C in a 5% CO 2 
end-point analysis 24|
To perform end-point analysis for 2D kidney organoids, follow option A below; for end-point analysis of 3D kidney organoids by frozen sectioning, follow option B; and for end-point analysis of 3D kidney organoids by whole-mount staining, follow option C.
